General
Preferred name
TERIPARATIDE
Synonyms
Parathyroid Hormone 1-34, Human ()
Forteo ()
Teriparatide recombinant human ()
Pth (1-34) ()
(1-34)-human parathyroid hormone ()
LY 333334 ()
Qutavina ()
Teriparatide sun ()
Movymia ()
Human parathyroid hormone 1-34 ()
LY-333334 ()
Livogiva ()
Teriparatide rdna ()
LY333334 ()
Forsteo ()
Kauliv ()
Teriparatida ()
Sondelbay ()
Terrosa ()
ZT-034 ()
1-34-human pth ()
Bonsity ()
Parathyroid Hormone (1-34) (human) (trifluoroacetate salt) ()
P&D ID
PD071716
CAS
52232-67-4
Tags
available
drug
Approved by
FDA
PMDA
EMA
First approval
2002
Drug indication
Psoriatic disorder
Osteogenesis imperfecta
bone fracture
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Teriparatide is a synthetic peptide of amino acids 1-34 of the N-terminal of human parathyroid hormone (). The PubChem and ChEMBL entries linked to above both display a chemical structure for teriparatide. Compare this to the clinical candidate peptide which is a synthetic analogue of human parathyroid hormone-related protein () .
Teriparatide biosimilars and non-originator biologicals are available in countries where patents have already expired. The patents on the reference agent Forteo/Forsteo expire in the US and in Europe in August 2019. The table below lists teriparatide biosimilars that are already approved or are in development.
(GtoPdb)
Teriparatide biosimilars and non-originator biologicals are available in countries where patents have already expired. The patents on the reference agent Forteo/Forsteo expire in the US and in Europe in August 2019. The table below lists teriparatide biosimilars that are already approved or are in development.
| Product name | Company | Clinical phase | Reference |
|---|---|---|---|
| teriparatide similar biologic | Intas Pharmaceuticals | Approved (India 2010) | |
| teriparatide similar biologic | Cadila Healthcare | Approved (India 2012) | |
| teriparatide similar biologic | USV | Approved (India 2012) | |
| Terrosa | Gedeon Richter | Approved (EMA 2017) | |
| Movymia | STADA Arzneimittel AG | Approved (EMA 2017) | |
| Bonsity (PF708) | Pfenex | Approved (FDA 2019) | |
| Sondelbay | Accord Healthcare | Approved (EMA 2022) | |
| Teriparatide Sun | Sun Pharmaceutical Industries | Approved (EMA 2022) | |
| Kauliv | Strides Pharma | Approved (EMA 2023) |
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
12
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
Natural product-based probes and drugs
Other bioactive compounds
ReFrame library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
45
Molecular Weight
4115.13
Hydrogen Bond Acceptors
57
Hydrogen Bond Donors
60
Rotatable Bonds
144
Ring Count
6
Aromatic Ring Count
6
cLogP
-15.24
TPSA
1752.65
Fraction CSP3
0.62
Chiral centers
34.0
Largest ring
6.0
QED
0.01
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Osteoporosis
Therapeutic Class
Hormone Therapy
Bone Density Conservation Agents
Source data
